A Recombinant Chimeric Protein-Based Vaccine Containing T-Cell Epitopes from Amastigote Proteins and Combined with Distinct Adjuvants, Induces Immunogenicity and Protection against Leishmania infantum Infection
Sign Up to like & getrecommendations! Published in 2022 at "Vaccines"
DOI: 10.3390/vaccines10071146
Abstract: Currently, there is no licensed vaccine to protect against human visceral leishmaniasis (VL), a potentially fatal disease caused by infection with Leishmania parasites. In the current study, a recombinant chimeric protein ChimT was developed based… read more here.
Keywords: recombinant chimeric; cell; chimt; immunogenicity ... See more keywords